Lifeward Ltd

Lifeward Ltd(LFWD)股票分析

$5.810

+0.071 (+1.22%)收盤時

Loading chart…
最高
5.964
開盤
5.650
成交量加權均價
5.81
成交量
5.03K
市值
—
最低
5.650
成交金額
29.19K
企業價值/稅息折舊攤銷前利潤(TTM)
-0.85

Lifeward Ltd, formerly known as ReWalk Robotics Ltd, is a medical device company. The Company is engaged in designing, developing, and commercializing exoskeletons that allow individuals with mobility impairments or other medical conditions the ability to stand and walk again. The Company offers an exoskeleton that uses its tilt-sensor technology and an onboard computer and motion sensors to drive motorized legs that power movement. Lifeward designs are intended for people with paraplegia, a spinal cord injury resulting in complete or incomplete paralysis of the legs, having the use of their upper bodies and arms. The Company offers multiple products: ReWalk Personal, ReStore Exo-Suit, MYOLYN FES Cycling, and AlterG Anti-Gravity Systems. ReWalk Personal is designed for everyday use by paraplegic individuals at home and in their communities and is custom-fitted for each user. Lifeward Rehabilitation products are for use by paraplegia patients in the clinical rehabilitation environment.

AI 分析 of Lifeward Ltd (LFWD)

持有

ReWalk Robotics Ltd (LFWD) is not a good buy right now due to its current price of $5.81 being significantly below its 52-week high of $9.61, and the RSI at 45.1 suggests it is neither overbought nor oversold, indicating a lack of strong momentum. Additionally, the company reported a net income loss of $11.5 million in Q2 2026, which raises concerns about its profitability.

估值指標

Lifeward Ltd(LFWD)目前預期本益比為 0.00,5 年平均預期本益比為 -2.96。

預期本益比

高估
5 年均值 P/E
-2.96
目前P/E
0.00
高估
-1.37
低估
-4.55

預期 EV/EBITDA

低估
5 年均值 EV/EBITDA
-0.08
目前EV/EBITDA
-0.85
高估
0.50
低估
-0.66

預期股價營收比

合理
5 年均值 P/S
2.58
目前P/S
0.39
高估
5.94
低估
-0.77

Alphio AI 對 LFWD 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%LFWD

$1.83

情境價格

基

基準

基準 · 50%LFWD

$1.53

情境價格

悲

悲觀

悲觀 · 25%LFWD

$1.30

情境價格

事件時間軸

2026-10-01 (ET)

10:00:00

Rewalk Robotics LTD Trading Halted Due to Volatility

2026-08-31 (ET)

16:30:00

Lifeward Appoints Josh Hexter as Interim CEO

2026-08-03 (ET)

09:30:00

Company Not Selling 2.07M Ordinary Shares

2026-05-19 (ET)

08:30:00

Lifeward Appoints Keith Rose as Chief Medical Officer

2026-04-27 (ET)

17:10:00

Lifeward Files to Sell 7.26M Ordinary Shares

資訊

LFWD 常見問題 —— 由 Alphio AI 解答

Lifeward Ltd, formerly known as ReWalk Robotics Ltd, is a medical device company. The Company is engaged in designing, developing, and commercializing exoskeletons that allow individuals with mobility impairments or other medical conditions the ability to stand and walk again. The Company offers an exoskeleton that uses its tilt-sensor technology and an onboard computer and motion sensors to drive motorized legs that power movement. Lifeward designs are intended for people with paraplegia, a spinal cord injury resulting in complete or incomplete paralysis of the legs, having the use of their upper bodies and arms. The Company offers multiple products: ReWalk Personal, ReStore Exo-Suit, MYOLYN FES Cycling, and AlterG Anti-Gravity Systems. ReWalk Personal is designed for everyday use by paraplegic individuals at home and in their communities and is custom-fitted for each user. Lifeward Rehabilitation products are for use by paraplegia patients in the clinical rehabilitation environment. It operates in the Healthcare sector (ORTHOPEDIC, PROSTHETIC, AND SURGICAL APPLIANCES AN industry).

ReWalk Robotics Ltd (LFWD) is not a good buy right now due to its current price of $5.81 being significantly below its 52-week high of $9.61, and the RSI at 45.1 suggests it is neither overbought nor oversold, indicating a lack of strong momentum. Additionally, the company reported a net income loss of $11.5 million in Q2 2026, which raises concerns about its profitability.

暫無貼文

註冊或登入後參與討論

相關文章

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易